What Is Melanotan II?
Pharmaqo MT-2 10mg
Melanotan II is a laboratory-created peptide that mimics the natural melanocyte-stimulating hormone (MSH) found in the body. It is designed to stimulate melanogenesis, the process responsible for producing melanin in the skin. In addition to its effects on pigmentation, it has also been associated with increased libido and sexual arousal.
Melanotan is most commonly used for skin tanning purposes. It has also been explored for other uses, including supporting erectile function in men with erectile dysfunction (ED), and for conditions such as rosacea and fibromyalgia. However, there is limited scientific evidence supporting many of these applications. There are also safety concerns regarding its use, particularly when administered as a subcutaneous injection.
Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). By activating melanocortin receptors, it promotes melanin production and may influence sexual desire.
Potential Effects on the Kidneys
There are concerns about possible kidney-related risks associated with misuse or adverse reactions. Reported risks may include:
-
Toxic effects on renal (kidney) tissue
-
Muscle breakdown (rhabdomyolysis), which can release myoglobin into the bloodstream
-
Myoglobin accumulation may place stress on the kidneys
-
In severe cases, this could potentially contribute to kidney impairment
Proper medical supervision is essential when considering any peptide-based compound.
Active Metabolite
Bremelanotide (PT-141) is considered an active metabolite associated with many of Melanotan II’s effects, particularly those related to sexual function.
How Does It Work?
Melanotan acts similarly to the body’s natural melanocyte-stimulating hormone. Its primary function is to stimulate the production of melanin, leading to increased skin pigmentation.
In addition to its tanning effects, Melanotan may act on certain receptors in the brain that influence sexual arousal and erectile response.





Reviews
There are no reviews yet.